OIPE JC106
JUN 10 2004
PATENT & TRADEMARK OFFICE

IFW

PATENT
Attorney Docket No. P05859US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	Link et al.	Group Art Unit: 1614
SERIAL NO:	10/682,178	Examiner:
FILED:	August 19, 2003	Confirmation No: 7316
TITLE:	ANTITUMOR VACCINATION USING ALLOGENEIC TUMOR CELLS EXPRESSING ALPHA (1,3)-GALACTOSYLTRANSFERASE	

INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING DATE OF EITHER A FINAL ACTION
OR NOTICE OF ALLOWANCE (37 C.F.R. § 1.97(c))

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This information disclosure statement is being filed ***before*** the mailing date of either a final action under § 1.113 or a notice of allowance under § 1.311, whichever occurs first.

Attached are Forms PTO/SB/08A and 08B (formerly Form PTO-1449) listing the relevant art known to the applicant herein. Copies of the references are enclosed. The Examiner is requested to consider the references and make them of record.

Applicant discloses herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose. Legible copies of all items listed in Forms PTO/SB/08A

CERTIFICATE OF MAILING/TRANSMISSION (37 CFR 1.8(a))

I hereby certify that this correspondence is, on the date shown below, being:

MAILING
☒ deposited with the United States Postal Service with sufficient postage as First Class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: 6/8/04

FACSIMILE
☐ transmitted by facsimile to the Patent and Trademark Office, Art Unit 1632 at Fax No. (703) 872-9306.

HEIDI S. NEBEL

and 08B (formerly Form PTO-1449) accompany this information statement, except those identified above.

Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement. A copy of the International Search Report is enclosed.

Authorization is hereby made to charge any additional fees required by this paper or credit any overpayment to Deposit Account 26-0084.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. (Notice of January 9, 1992, 1135 O.G. 13-25, at 25.)

Respectfully submitted,

HEIDI S. NEBEL, Reg. No. 37,719
McKEE, VOORHEES & SEASE, P.L.C.
801 Grand Avenue, Suite 3200
Des Moines, Iowa 50309-2721
Phone No. (515) 288-3667
Fax No. (515) 288-1338
CUSTOMER NO: 22885

- pw -

Attorneys of Record

OIPE JC106
JUN 10 2004
PATENT & TRADEMARK OFFICE

Form PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	10/643,829
Filing Date	August 19, 2003
First Named Inventor	LIU, His-Chou
Group Art Unit	1632
Examiner Name	
Attorney Docket Number	P05779US01

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. [1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	1	International Search Report for co-pending PCT Application No. PCT/US03/32036	
	2	Galili U et al., "Preparation of autologous leukemia and lymphoma vaccines expressing alpha-gal epitopes", Journal of Hematotherapy and Stem Cell Research. U.S. August 2001; 10(4):501-511 August 2001	
	3	LaTemple D.C. et al., "Synthesis of α-Galactosyl Epitopes by Recombinant α1,3Galactosyltransferase for Opsonization of Human Tumor Cell Vaccines by Anti-Galactose", Cancer Research, American Association for Cancer Research, Baltimore, Md, US, 56:3069-3074; July 1996	
	4	LaTemple, Denise C. et al., "Increased immunogenicity of tumor vaccines complexed with anti-gal: Studies in knockout mice for α1, 3galactosyltransferase", Cancer Research, American Association for Cancer Research, Baltimore, MD, US, 59(4):3417-3423; July 1999	
	5	Gorelik E., et al., "Alterations of cell surface carbohydrates and inhibition of metastatic property of murine melanomas by α1,3 galactosyltransferase gene transfection", Cancer Research, American Association for Cancer Research, Baltimore, Md, US, 55(18):4168-4173; September 1995	
	6	Galili Uri et al., "Expression of α-gal epitopes on ovarian carcinoma membranes to be used as a novel autologous tumor vaccine", Gynecologic Oncology, 90(1):100-108; July 2003	
	7	Yoshimura N. et al., "Expression of xenoantigen transformed human cancer cells to be susceptible to antibody-mediated cell killing", Cancer Letters. Ireland 164(2):155-160; March 2001	

Examiner Signature		Date Considered	

* EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.